CSL Limited (CSL.AX)
| Previous close | 288.79 |
| Open | 288.51 |
| Bid | 290.90 x 0 |
| Ask | 292.90 x 0 |
| Day's range | 286.92 - 293.30 |
| 52-week range | 228.65 - 313.55 |
| Volume | |
| Avg. volume | 652,624 |
| Market cap | 141.64B |
| Beta (5Y monthly) | 0.32 |
| PE ratio (TTM) | 36.61 |
| EPS (TTM) | 7.99 |
| Earnings date | 13 Aug 2024 |
| Forward dividend & yield | 3.97 (1.36%) |
| Ex-dividend date | 09 Sept 2024 |
| 1y target est | 327.30 |
PR NewswireCSL Seqirus, a Global Leader in Pandemic Preparedness, Announces Sixth BARDA Award in Response to Avian Influenza
CSL Seqirus, a business of CSL (ASX: CSL), has been selected by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS), to fill and finish additional pre-pandemic vaccine doses as part of the National Pre-Pandemic Influenza Vaccine Stockpile (NPIVS). This latest acquisition of pre-pandemic vaccine will further supplement BARDA's stockpile of vaccine
BloombergSanofi, GSK, CSL Tapped to Expand US Bird Flu Vaccine Supply
(Bloomberg) -- GSK Plc, Sanofi and CSL Ltd. secured $72 million from the US government to ramp up production of bird flu vaccines as a nationwide outbreak among livestock and poultry has led to several human infections that have raised concerns about further spread.Most Read from BloombergSingapore Ends 181 Years of Horse Racing to Make Way for HomesWhat Do US Vehicle Regulators Have Against Tiny Cars?For a Master of Brutalist Provocations, a Modest Museum AppraisalMexico City Restricts Airbnb R
ZacksEXEL vs. CSLLY: Which Stock Is the Better Value Option?
EXEL vs. CSLLY: Which Stock Is the Better Value Option?
